Thirty-three stage IIIAand IIIBpatients with Hodgkin's disease have been treated with a combination chemotherapy-radiotherapy program for the past five years. In this program, chemotherapy was administered prior to radiotherapy. The primary purpose for administering preliminary chemotherapy was to insure completion of a scheduled program of radiotherapy. A possible secondary advantage may be a reduction in the incidence of subsequent new disease. Initially, our drug regimen consisted of one course of cyclophosphamide and vincrinstine sulfate. When procarbazine hydrochloride became available, our chemotherapy program was changed to a combination of mechlorethamine hydrochloride, vincristine sulfate (Oncovin), procarbazine hydrochloride, and prednisone (MOPP). Two courses of MOPP were used initially; later the number of courses was changed to three. Survival figures for three and five years are 70% and 68%, respectively.